Monoclonal Antibodies against Nucleocapsid Protein of SARS-CoV-2 Variants for Detection of COVID-19

Código QR

Monoclonal Antibodies against Nucleocapsid Protein of SARS-CoV-2 Variants for Detection of COVID-19

Mitigation strategies of the coronavirus disease 2019 (COVID-19) pandemic have been greatly hindered by the continuous emergence of SARS-CoV-2 variants. New sensitive, rapid diagnostic tests for the wide-spectrum detection of viral variants are needed. We generated a panel of 41 monoclonal antibodie...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ruei-Min Lu, Shih-Han Ko, Wan-Yu Chen, Yu-Ling Chang, Hsiu-Ting Lin, Han-Chung Wu
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	COVID-19 SARS-CoV-2 antibody nucleocapsid protein rapid test LFIA Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/48a723907e214b449fcf2ffaf9e493f8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2
por: Gururaj Rao Deshpande, et al.
Publicado: (2021)

Production and Characterization of Nucleocapsid and RBD Cocktail Antigens of SARS-CoV-2 in <i>Nicotiana benthamiana</i> Plant as a Vaccine Candidate against COVID-19
por: Tarlan Mamedov, et al.
Publicado: (2021)

Antibody cocktail effective against variants of SARS-CoV-2
por: Kang-Hao Liang, et al.
Publicado: (2021)

SARS-CoV-2 variants with T135I nucleocapsid mutations may affect antigen test performance
por: Ming-Jr Jian, et al.
Publicado: (2022)

Potential Vaccine Targets for COVID-19 and Phylogenetic Analysis Based on the Nucleocapsid Phosphoprotein of Indonesian SARS-CoV-2 Isolates
por: Muhammad Aldino, et al.
Publicado: (2021)

MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants
por: Sua Lee, et al.
Publicado: (2021)

Effective Prophylaxis of COVID-19 in Rhesus Macaques Using a Combination of Two Parenterally-Administered SARS-CoV-2 Neutralizing Antibodies
por: Brandon J. Beddingfield, et al.
Publicado: (2021)

Antibody Responses to SARS-CoV-2 Infection—Comparative Determination of Seroprevalence in Two High-Throughput Assays versus a Sensitive Spike Protein ELISA
por: Dinesh Mohanraj, et al.
Publicado: (2021)

Assessment of COVID-19 Incidence and the Ability to Synthesise Anti-SARS-CoV-2 Antibodies of Paediatric Patients with Primary Immunodeficiency
por: Karolina Pieniawska-Śmiech, et al.
Publicado: (2021)

Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect <italic toggle="yes">In Vivo</italic> in a Mouse Model in a Neutralization-Dependent Manner
por: Fatima Amanat, et al.
Publicado: (2021)

A Strategy to Detect Emerging Non-Delta SARS-CoV-2 Variants with a Monoclonal Antibody Specific for the N501 Spike Residue
por: Rama Devudu Puligedda, et al.
Publicado: (2021)

Antibody conversion rates to SARS-CoV-2 in saliva from children attending summer schools in Barcelona, Spain
por: Carlota Dobaño, et al.
Publicado: (2021)

AuNP Coupled Rapid Flow-Through Dot-Blot Immuno-Assay for Enhanced Detection of SARS-CoV-2 Specific Nucleocapsid and Receptor Binding Domain IgG
por: Sil BK, et al.
Publicado: (2021)

Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
por: Chin-Shern Lau, et al.
Publicado: (2021)

SARS‐CoV‐2 infection shortly after BNT162b2 vaccination results in high anti‐spike antibody levels in nursing home residents and staff
por: Doris Urlaub, et al.
Publicado: (2021)

SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape
por: Lin Yang, et al.
Publicado: (2021)

In silico identification of MicroRNAs targeting the key nucleator of stress granules, G3BP: Promising therapeutics for SARS-CoV-2 infection
por: Bjad K. Almutairy, et al.
Publicado: (2021)

Elevated Anti-SARS-CoV-2 Antibodies and IL-6, IL-8, MIP-1β, Early Predictors of Severe COVID-19
por: Helena Codina, et al.
Publicado: (2021)

Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020
por: Cheng Xiao, et al.
Publicado: (2021)

Tear antibodies to SARS‐CoV‐2: implications for transmission
por: Kevin J Selva, et al.
Publicado: (2021)

Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine
por: Felipe Melo-González, et al.
Publicado: (2021)

Common Laboratory Mice Are Susceptible to Infection with the SARS-CoV-2 Beta Variant
por: Ravi Kant, et al.
Publicado: (2021)

Evaluation of the performance of 25 SARS-CoV-2 serological rapid diagnostic tests using a reference panel of plasma specimens at the Uganda Virus Research Institute
por: Tom Lutalo, et al.
Publicado: (2021)

Dynamics of Neutralizing Antibody Responses Following Natural SARS-CoV-2 Infection and Correlation with Commercial Serologic Tests. A Reappraisal and Indirect Comparison with Vaccinated Subjects
por: Constant Gillot, et al.
Publicado: (2021)

Evolution of SARS-CoV-2-Neutralizing Antibodies after Two Standard Dose Vaccinations, Risk Factors for Non-Response and Effect of a Third Dose Booster Vaccination in Non-Responders on Hemodialysis: A Prospective Multi-Centre Cohort Study
por: Frank-Peter Tillmann, et al.
Publicado: (2021)

Herd immunity to SARS-CoV-2 among the population of the Republic of Belarus amid the COVID-19 pandemic
por: A. Yu. Popova, et al.
Publicado: (2021)

Berberine Chloride is an Alphavirus Inhibitor That Targets Nucleocapsid Assembly
por: Judy J. Wan, et al.
Publicado: (2020)

Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities
por: Xiaodong Tian, et al.
Publicado: (2021)

Reactions and COVID-19 disease progression following SARS-CoV-2 monoclonal antibody infusion
por: Laurel Goldin, et al.
Publicado: (2021)

Detection of Antibodies Against the SARS-CoV-2 Spike Protein and Analysis of the Peripheral Blood Mononuclear Cell Transcriptomic Profile, 15 Years After Recovery From SARS
por: Lili Zhao, et al.
Publicado: (2021)

High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2
por: Rita Jaafar, et al.
Publicado: (2021)

Monoclonal Human Antibodies That Recognise the Exposed N and C Terminal Regions of the Often-Overlooked SARS-CoV-2 ORF3a Transmembrane Protein
por: Tyng Hwey Tan, et al.
Publicado: (2021)

XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants
por: Bernard Vanhove, et al.
Publicado: (2021)

Neutralizing antibody response to SARS-CoV-2 persists 9 months post symptom onset in mild and asymptomatic patients
por: Olivier Bylicki, et al.
Publicado: (2021)

Comparative Sensitivity of Rapid Antigen Tests for the Delta Variant (B.1.617.2) of SARS-CoV-2
por: Yuko Sakai-Tagawa, et al.
Publicado: (2021)

Recovery from Acute SARS-CoV-2 Infection and Development of Anamnestic Immune Responses in T Cell-Depleted Rhesus Macaques
por: Kim J. Hasenkrug, et al.
Publicado: (2021)

Diagnostic Performance of Automated SARS-CoV-2 Antigen Assay in Nasal Swab during COVID-19 Vaccination Campaign
por: Haya Altawalah, et al.
Publicado: (2021)

Durability of Antibody Responses to SARS-CoV-2 Infection and Its Relationship to Disease Severity Assessed Using a Commercially Available Assay
por: Alanoud Alshami, et al.
Publicado: (2021)

SARS-CoV-2 Spike Protein-Induced Interleukin 6 Signaling Is Blocked by a Plant-Produced Anti-Interleukin 6 Receptor Monoclonal Antibody
por: Collin Jugler, et al.
Publicado: (2021)

Two extraction-free reverse transcription loop-mediated isothermal amplification assays for detection of SARS-CoV-2
por: Meng Yee Lai, et al.
Publicado: (2021)